SynthesisBioengineered2022
Chinese patent medicine for osteoporosis: a systematic review and meta-analysis.
Synthesis in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 7 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Unveiling the efficacy predictors and potential mechanisms ofFrontiers in immunology · 2026Pooled it
- Gut microbiome and bone health: update on mechanisms, clinical correlations, and possible treatment strategies.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Pooled it
- The efficacy and safety of Gukang Capsule for primary osteoporosis: a systematic review and meta-analysis of randomized clinical trial.Frontiers in pharmacology · 2024Pooled it
- Additional effects of herbal medicine combined with bisphosphonates for primary osteoporosis: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Osteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysis.Frontiers in endocrinology · 2023Pooled it
- The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2023Pooled it
- Efficacy of the Chinese herbal medicine Jintiange capsules in the postoperative treatment of osteoporotic vertebral compression fractures: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Clinical efficacy of Teriparatide combining Zhuanggu Zhitong capsules in the treatment of osteoporosis.Pakistan journal of medical sciences · 2025Article
- Kuntai Capsules Improve Premature Ovarian Failure by Regulating AMPK-Mediated Autophagy.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Association between triglyceride‑glucose index and lumbar bone mineral density among Chinese individuals with osteoporotic fractures: a cross sectional study.Scientific reports · 2025Article
- Neuropeptides as regulators of bone metabolism: from molecular mechanisms to traditional Chinese medicine intervention strategies.Frontiers in pharmacology · 2025Review
- Exploring the mechanism of Heidihuang Pill in the treatment of osteoporosis based on network pharmacology, molecular docking, and experimental validation.Frontiers in endocrinology · 2025Article
- Albumin: a mediator of the association between serum calcium and triglyceride-glucose index among Chinese individuals with osteoporotic fractures.Frontiers in endocrinology · 2025Article
- Network Pharmacology and Experimental Validation of the Therapeutic Effect of Baji Capsule on LPS-Induced Osteoporosis.Orthopedic research and reviews · 2025Article
- Emerging Roles of Natural Compounds in Osteoporosis: Regulation, Molecular Mechanisms and Bone Regeneration.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Molecular mechanism of resveratrol promoting differentiation of preosteoblastic MC3T3-E1 cells based on network pharmacology and experimental validation.BMC complementary medicine and therapies · 2024Article
- Association of apolipoprotein A1 levels with lumbar bone mineral density and β-CTX in osteoporotic fracture individuals: a cross-sectional investigation.Frontiers in medicine · 2024Article
- Article
- The Synergistic Effect of Zuogui Pill and Eldecalcitol on Improving Bone Mass and Osteogenesis in Type 2 Diabetic Osteoporosis.Medicina (Kaunas, Lithuania) · 2023Article
- Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions.Chinese medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chinese patent medicine (CPM) has been widely used in China for patients with osteoporosis (OP) but a comprehensive literature review is still important. Therefore, we performed meta-analysis using six electronic databases prior to 30 April 2021 only randomized controlled trials (RCTs) using CPM as the first-line treatment in adults with OP were included. Thirty RCTs met the inclusion criteria with a total of 2723 patients, and seven types of CPM were included. Compared with the control group, 23 studies showed significantly improved bone mineral density (BMD) (lumbar spine) (mean difference [MD] = 0.08; confidence interval [CI], 0.03 to 0.13), 15 studies showed significantly improved BMD (femoral) (MD = 0.05; 95% CI, 0.02 to 0.07), 6 studies showed significantly improved BMD (radius) (MD = 0.06; 95% CI, 0.03 to 0.09), 2 trials showed significantly improvement of BMD (ulna) (MD = 0.02; 95% CI, 0.01 to 0.03), and 4 trials showed significantly improved BMD (MD = 0.09; 95% CI, 0.09 to 0.10). The meta-analysis also showed that CPM had superior pain improvement, a higher total effectiveness rate, and a lower risk of adverse events compared with standard western treatment. The findings of this study suggest that CPM therapy may be a safe and effective alternative treatment modality for OP, it has potential benefits in relieving symptoms and improving BMD compared to western medications or placebos.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.